|
1
|
Raghu G, Remy-Jardin M, Richeldi L,
Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM,
Martinez FJ, et al: Idiopathic pulmonary fibrosis (an update) and
progressive pulmonary fibrosis in adults: An official
ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care
Med. 205:e18–e47. 2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Maher TM, Bendstrup E, Dron L, Langley J,
Smith G, Khalid JM, Patel H and Kreuter M: Global incidence and
prevalence of idiopathic pulmonary fibrosis. Respir Res.
22(197)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cottin V, Tomassetti S, Valenzuela C,
Walsh SLF, Antoniou KM, Bonella F, Brown KK, Collard HR, Corte TJ,
Flaherty KR, et al: Integrating clinical probability into the
diagnostic approach to idiopathic pulmonary fibrosis: An
international working group perspective. Am J Respir Crit Care Med.
206:247–259. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Barratt SL, Creamer A, Hayton C and
Chaudhuri N: Idiopathic pulmonary fibrosis (IPF): An overview. J
Clin Med. 7(201)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chambers RC and Mercer PF: Mechanisms of
alveolar epithelial injury, repair, and fibrosis. Ann Am Thorac
Soc. 12 (Suppl 1):S16–S20. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chanda D, Otoupalova E, Smith SR,
Volckaert T, De Langhe SP and Thannickal VJ: Developmental pathways
in the pathogenesis of lung fibrosis. Mol Aspects Med. 65:56–69.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Schafer MJ, White TA, Iijima K, Haak AJ,
Ligresti G, Atkinson EJ, Oberg AL, Birch J, Salmonowicz H, Zhu Y,
et al: Cellular senescence mediates fibrotic pulmonary disease. Nat
Commun. 8(14532)2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Königshoff M, Balsara N, Pfaff EM, Kramer
M, Chrobak I, Seeger W and Eickelberg O: Functional Wnt signaling
is increased in idiopathic pulmonary fibrosis. PLoS One.
3(e2142)2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Newman DR, Sills WS, Hanrahan K, Ziegler
A, Tidd KM, Cook E and Sannes PL: Expression of WNT5A in idiopathic
pulmonary fibrosis and its control by TGF-β and WNT7B in human lung
fibroblasts. J Histochem Cytochem. 64:99–111. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Martin-Medina A, Lehmann M, Burgy O,
Hermann S, Baarsma HA, Wagner DE, De Santis MM, Ciolek F, Hofer TP,
Frankenberger M, et al: Increased vesicles mediate WNT5A signaling
in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.
198:1527–1538. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Königshoff M, Kramer M, Balsara N, Wilhelm
J, Amarie OV, Jahn A, Rose F, Fink L, Seeger W, Schaefer L, et al:
WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in
mice and is upregulated in humans with idiopathic pulmonary
fibrosis. J Clin Invest. 119:772–787. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Berschneider B and Königshoff M: WNT1
inducible signaling pathway protein 1 (WISP1): A novel mediator
linking development and disease. Int J Biochem Cell Biol.
43:306–309. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Baarsma H and Königshoff M: ‘WNT-er is
coming’: WNT signalling in chronic lung diseases. Thorax.
72:746–759. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mahler DA and Wells CK: Evaluation of
clinical methods for rating dyspnea. Chest. 93:580–586.
1988.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Oldham JM, Neely Wojdyla DM, Gulati M, Li
P, Patel DC, Palmer SM and Todd JL: IPF-PRO Registry Investigators.
Changes in lung function and mortality risk in patients with
idiopathic pulmonary fibrosis. Chest. 168:415–422. 2025.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sharma S, Tantisira K, Carey V, Murphy AJ,
Lasky-Su J, Celedón JC, Lazarus R, Klanderman B, Rogers A,
Soto-Quirós M, et al: A role for Wnt signaling genes in the
pathogenesis of impaired lung function in asthma. Am J Respir Crit
Care Med. 181:328–336. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Carlier FM, Dupasquier S, Ambroise J,
Detry B, Lecocq M, Biétry-Claudet C, Boukala Y, Gala JL, Bouzin C,
Verleden SE, et al: Canonical WNT pathway is activated in the
airway epithelium in chronic obstructive pulmonary disease.
EBioMedicine. 61(103034)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Guiot J, Henket M, Corhay JL, Moermans C
and Louis R: Sputum biomarkers in IPF: Evidence for raised gene
expression and protein level of IGFBP-2, IL-8 and MMP-7. PLoS One.
12(e0171344)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chilosi M, Poletti V, Zamò A, Lestani M,
Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, et
al: Aberrant Wnt/beta-catenin pathway activation in idiopathic
pulmonary fibrosis. Am J Pathol. 162:1495–1502. 2003.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wu X, van Dijk EM, Ng-Blichfeldt JP, Bos
IST, Ciminieri C, Königshoff M, Kistemaker LEM and Gosens R:
Mesenchymal WNT-5A/5B signaling represses lung alveolar epithelial
progenitors. Cells. 8(1147)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Koçak A, Harmancı D, Güner Akdoğan G and
Birlik M: Relationship of Wnt pathway activity and organ
involvement in scleroderma types. Int J Rheum Dis. 23:1558–1567.
2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Al-Kuraishy HM, Batiha GE, Faidah H,
Al-Gareeb AI, Saad HM and Simal-Gandara J: Pirfenidone and
post-Covid-19 pulmonary fibrosis: Invoked again for realistic
goals. Inflammopharmacology. 30:2017–2026. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ding H, Chen J, Qin J, Chen R and Yi Z:
TGF-β-induced α-SMA expression is mediated by C/EBPβ acetylation in
human alveolar epithelial cells. Mol Med. 27(22)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cohen ML, Brumwell AN, Ho TC, Garakani K,
Montas G, Leong D, Ding VW, Golden JA, Trinh BN, Jablons DM, et al:
A fibroblast-dependent TGF-β1/sFRP2 noncanonical Wnt signaling axis
promotes epithelial metaplasia in idiopathic pulmonary fibrosis. J
Clin Invest. 134(e174598)2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li X, Liu X, Deng R, Gao S, Yu H, Huang K,
Jiang Q, Liu R, Li X, Zhang L, et al: Nintedanib inhibits
Wnt3a-induced myofibroblast activation by suppressing the
Src/β-catenin pathway. Front Pharmacol. 11(310)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Koçak A, Gülle S and Birlik M: Porcupine
inhibitors LGK-974 and ETC-159 inhibit Wnt/β-catenin signaling and
result in inhibition of the fibrosis. Toxicol In Vitro.
104(105986)2025.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Shah K, Panchal S and Patel B: Porcupine
inhibitors: Novel and emerging anti-cancer therapeutics targeting
the Wnt signaling pathway. Pharmacol Res.
167(105532)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rodon J, Argilés G, Connolly RM,
Vaishampayan U, de Jonge M, Garralda E, Giannakis M, Smith DC,
Dobson JR, McLaughlin ME, et al: Phase 1 study of single-agent
WNT974, a first-in-class porcupine inhibitor, in patients with
advanced solid tumours. Br J Cancer. 125:28–37. 2021.PubMed/NCBI View Article : Google Scholar
|
